Raub Brock Capital Management LP Amgen Inc Transaction History

Raub Brock Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 23, 2019	SELL	$166.7 - $195.41 $16.6 Million - $19.4 Million	-99,457 Closed	0 $0
Q1 2019 Apr 25, 2019	BUY	$180.87 - $203.88 $506,797 - $571,271	2,802 Added 2.9%	99,457 $18.9 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $391,588 - $457,108	2,195 Added 2.32%	96,655 $18.8 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $93,200 - $105,071	-503 Reduced 0.53%	94,460 $19.6 Million
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $657,890 - $738,952	3,962 Added 4.35%	94,963 $17.5 Million
Q1 2018 Apr 16, 2018	BUY	$169.43 - $198.0 $209,754 - $245,124	1,238 Added 1.38%	91,001 $15.5 Million
Q4 2017 Jan 04, 2018	SELL	$168.79 - $188.59 $370,325 - $413,766	-2,194 Reduced 2.39%	89,763 $15.6 Million
Q3 2017 Oct 12, 2017	BUY	$167.29 - $191.0 $15.4 Million - $17.6 Million	91,957	91,957 $17.1 Million

3,075

417M

7.19M

6.28M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Raub Brock Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Raub Brock Capital Management LP with notifications on news.